Sales & Marketing How data is critical to commercialising drugs for rare disea... Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.
R&D Pharma gets ruthless as job losses mount across industry The industry is showing its teeth, as companies have started slashing positions.
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
